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The quotation above has led to the commonly held view that all bacteria will eventually become resistant to any antibiotic given enough time and exposure.
However not all bacteria develop resistance to antibiotics at the same rate (and perhaps some species of bacteria may never develop resistance to certain antibiotics). And some bacteria that have been labeled "resistant" are not, in any clinically meaningful way, actually resistant (i.e. result in a therapeutic failure).
Indeed, all antibiotics, even within the same chemical class, are not created equal (in terms of their propensity to select for resistant strains).
Another piece of dubious conventional wisdom is that bacterial resistance to drug therapy was first discovered following the introduction of penicillin." When narrowly parsed this statement is true (in that one can only find therapeutic failure of a drug when that drug is used therapeutically) but the fact is that the first description of a beta-lactamase producing (and therefore penicillin resistant) . This is despite both being members of the same of class of antibiotics and sharing a similar spectrum of antibacterial activity. Should this rather controversial result be valid, none of our current resistance dogma can account for this observation.
Are there differential affects on commensal microflora at work here? If so this may mean that we grossly underestimate the importance of commensal microflora and how they are be affected by antibiotic use or even protect their human hosts from infection by pathogenic bacteria. It certainly demonstrates that all antibiotics, even within the same class, are not created equal.
It is observed here that the ability of a given bacterium to evolve towards a multidrug resistance phenotype is a function of genome size. In the Table a number of examples are provided but even an expanded analysis shows that this observation holds true. That is the larger the genome the greater the propensity of a bacterium to display multidrug resistant phenotypes and that the smaller the
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on July 7, 2017 by guest http://aac.asm.org/ genome the less likely antibacterial resistance will emerge and disseminate within that species. What is proposed here is that, just as there is a continuum of genome sizes among bacteria, there is a continuum in the ability/propensity of a bacterium to become "multidrug resistant" and that continuum is reflected in the size of the genome. This is not to say that we do not observe resistance to certain agents in even the smallest genome organisms (macrolide resistance appears in virtually every pathogen at some level). There is probably a solid biological reason for this observation; larger genome organisms are more adaptable to environmental changes because they have more (genetic) information to draw upon. It appears that smaller genome organisms have become more "specialized" residing in particular environmental niches (T.
pallidum and the Chlamydia cases in point) and their lack of versatility in adapting to different environments is also manifest in an inability to develop antibiotic coping mechanisms. Indeed we have learned that virtually each and every time a bacterium either acquires a novel resistance determinants or a mutant strain arises with decreased susceptibility to an antibacterial drug the bacterium experiences a "fitness burden." With time compensatory mutations are selected in which the bacterium accumulates mutations that allow for something like wild type growth in a strain that is now phenotypically resistant (e.g. topA mutants in gyrB mutant strains) 5, 6 . The larger genome bacteria simply have a greater opportunity to develop these compensatory mutations. It must be emphasized that it does not matter whether we discussing acquisition of novel resistance gene as opposed to a mutation that alters the target or results in upregulation of an efflux pump. The accumulating evidence tells us that all require some form of adaptation. Another consequence of this phenomenon is that antibiotic cycling in health care settings is unlikely to result in a reversion of the local microflora to susceptibility as the compensatory mutations "lock in" the resistant phenotype.
Consistent with the "size matters" hypothesis is the common observation that it is very difficult to develop genetic systems in small genome organisms, anyone The author and several of those he has discussed this observation with were perplexed that it had not previously been articulated. Although to be fair others have suggested it is a trivial, if not nonsensical observation, and worthy only of cocktail party conversation…in fact the author believes that this is an important guide as to where and which organisms we actually need novel antibacterial propose more global studies on bacterial drug resistance and microbial ecology with "lack of focus" (rather than quality of science, or public health significance)

being the principle criticism. Such laser like focus precludes the big picture to the point of obscuring the obvious.
And in the face of so much misleading conventional wisdom the author asks:
How can we control resistance to antibacterial agents when we do not 
